Cellebrite DI (CLBT) reports quarterly results on Thursday

Cellebrite DI (NASDAQ:CLBT – Get Free Report) is expected to report its earnings results before the market opens on Thursday, August 15th. Analysts expect that the company will report earnings of $0.07 per share for the quarter. Those wishing to listen to the company’s earnings conference call can do so by following this link.

Cellebrite DI (NASDAQ: CLBT – Get Free Report) last released quarterly earnings results on Thursday, May 23. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $89.60 million during the quarter, compared to analysts’ expectations of $85.34 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The company’s revenue increased 25.8% year-over-year. In the year-ago quarter, the company posted $0.03 EPS. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Stock Performance

Shares of Cellebrite DI opened at $13.34 on Tuesday. The company has a 50-day moving average of $12.26 and a 200-day moving average of $11.40. Cellebrite DI has a 52-week low of $6.36 and a 52-week high of $14.11.

Analysts set new price targets

Several equities research analysts have recently weighed in on CLBT stock. Needham & Company LLC increased their price target on Cellebrite DI from $13.50 to $14.00 and gave the stock a “buy” rating in a research note on Friday, May 24th. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, May 24th. Finally, Lake Street Capital initiated coverage on shares of Cellebrite DI in a research note on Friday, April 19th. They set a “buy” rating and a $13.00 price target for the company. Six analysts have rated the stock with a “buy” rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $14.00.

Get our latest stock analysis on CLBT

About Cellebrite DI

(Get free report)

Cellebrite DI Ltd. develops solutions for regulatory investigations in Europe, the Middle East, Africa, the Americas and Asia Pacific. The company’s DI solutions enable users to collect, review, analyze and manage digital data throughout the investigation cycle for regulatory investigations used in a variety of cases including child exploitation, homicide, counter-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency and intellectual property theft.